

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **LifeTech Scientific Corporation**

**先健科技公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1302)**

### **VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT OF THE COMPANY**

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with information on the latest product development of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 30 October 2015, the FIM (First in Man) clinical trial of the Group’s GoldenFlow™ peripheral stents (“**GoldenFlow**”) in the Prince of Wales Hospital in Hong Kong was successfully completed on two patients using three sets of GoldenFlow. This was the first time GoldenFlow was ever implanted in human bodies in the world. The implantation of GoldenFlow into patients and the related surgeries conducted during the clinical trial were all smooth and successful and the GoldenFlow implanted were all accurately positioned and easily released inside the patients’ bodies, which demonstrated the high degree of safety of GoldenFlow.

Unlike most of the other peripheral stents on the market, GoldenFlow is a braided stent. GoldenFlow has overcome the shortcomings commonly found in laser-cutting stents such as weak support, easy to break, not retrievable, and fatigue-prone. Given the special stent design and weave pattern of GoldenFlow, as well as the self-compensating function of the delivery system, GoldenFlow has also solved the problem of difficult positioning due to the high foreshortening rate of traditional braiding peripheral stents.

The Board believes that in addition, GoldenFlow has many other advantages including high flexibility and fatigue resistance given it is a braided outer periphery bare-metal stent, good support for vascular plaque as its stent radial strength is at least a few times higher than that of the ordinary laser cutting stents, accurate positioning and easy release during implantation due to its unique self-compensating delivery system and segmented stent design, and easy to use.

In light of the satisfactory result of the clinical trial of GoldenFlow as mentioned above and the advantages GoldenFlow has over other peripheral stents, the Company expects that the said product will become significant to the Company's sales in the future.

By Order of the Board  
**LifeTech Scientific Corporation**  
**XIE Yuehui**  
*Chairman, Chief Executive Officer  
and Executive Director*

Hong Kong, 4 November 2015

*As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. WU Jianhui, Mr. MONAGHAN Shawn Del, Mr. JIANG Feng and Mr. CLEARY Christopher Michael being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. ZHOU Gengshen and Mr. ZHOU Luming being independent non-executive Directors.*